Labcorp to Present Combined Oncology Offering at ASCO® 2021 Annual Meeting


BURLINGTON, NC – (COMMERCIAL THREAD) – Labcorp (NYSE: LH), a leading global life science company, today announced the introduction of its combined Labcorp oncology platform at the American Society of Clinical Oncology (ASCO)®) Annual meeting held from June 4 to 8.

Labcorp’s Oncology Platform brings together the company’s leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions for oncology by leveraging groundbreaking science and insights clinical and patient data to make better decisions and improve patient outcomes. Labcorp’s highly trained and specialized oncology team is led by Prasanth Reddy, MD, MPH, a triple certified oncologist, and includes Robert Phillips, Ph.D., vice president and chief corporate officer.

“Advances in science have led to some promising cancer-related discoveries, but there is still a long way to go in oncology to find better treatments and improve lives,” said Phillips. “Labcorp is used to developing top-notch diagnostic and drug development solutions that can help accelerate new treatment options for cancer patients. We are able to enable better decisions and make precision medicine accessible to more cancer patients by expanding access to diagnostic testing and clinical trial opportunities in all communities. ”

Phillips will speak at the Industry Expert Theater1 Monday, June 7 from 10 a.m. to 10:40 a.m. EDT. Its presentation, Reinventing precision medicine throughout a patient’s journey, will present the Labcorp oncology platform and highlight new and extensive testing and trial options. Immediately following the presentation, Phillips will host a live question-and-answer session with the audience. Participants will also have on-demand access to the presentation for the duration of the conference. Labcorp’s online exhibit for the ASCO Annual Meeting is available 24/7 from Friday May 14 through Tuesday July 6. The exhibition aims to educate attendees about the testing options offered by Labcorp, as well as the broad support provided by the company. clinical trials in oncology. Participants will be able to leave a virtual business card on the exhibition page to connect with Labcorp. To access Dr Phillips’ online exhibit and presentation, and to learn more about the conference, please visit

Labcorp’s full menu of oncology tests to be discussed at the ASCO annual meeting includes the commercial introduction of OmniSeq® INSIGHT: A pan-cancer tissue sequencing test for patients with advanced solid tumor cancers. The test helps doctors make treatment decisions and identify patients who may be eligible for one of the thousands of ongoing clinical trials.

Labcorp also intends to highlight IntelliGEN® Myeloid and fluid biopsy tests for lung cancer. IntelliGEN® Myeloid is a next-generation sequencing assay (NGS) that evaluates 50 genes known to be useful in providing diagnostic, prognostic and predictive information for patients with myeloid malignancies. The liquid biopsy test examines a blood sample for cancer cells or pieces of DNA from a tumor circulating in the blood, to identify mutations and to help select the most effective treatments and more targeted. It is an increasingly viable and non-invasive testing option in cases where obtaining a tissue sample may be difficult or risky.

Labcorp Drug Development will contribute two online abstracts to the scientific program – e18608: “Mortality in adult patients with solid or hematologic cancers and SARS-CoV-2 infection with particular emphasis on malignant tumors of the lung and breast: a systematic review and meta-analysis, ”and e13584:“ The role of digital clinical measures in improving cancer care and research. ”

Labcorp also donated to Conquer Cancer®, the ASCO foundation dedicated to the fight against cancer in the world by funding cutting-edge research and sharing cutting-edge knowledge.

To learn more about Labcorp’s new oncology platform, visit us at

About Labcorp

Labcorp is a leading global life sciences company providing vital information to help physicians, hospitals, pharmaceutical companies, researchers and patients make clear and safe decisions. With our unmatched diagnostic and drug development capabilities, we deliver information and accelerate innovations to improve health and life. With over 70,000 employees, we serve customers in over 100 countries. Labcorp (NYSE: LH) reported revenue of $ 14.0 billion in fiscal 2020. Check out Labcorp at, or follow us on LinkedIn and Twitter @Labcorp.

1 Industry Expert Theater sessions and the presentation of Labcorp Reinventing precision medicine throughout a patient’s journey are not official presentations of the ASCO 2021 Annual Meeting, are not sponsored, endorsed or accredited by ASCO, and are not accredited by CME.

Source link

Leave A Reply

Your email address will not be published.